Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 0.762. It has been cited 19 times, with 11 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0.313
From 7 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 11 citers.
Bristol-Myers Squibb
Grant: ECOG-ACRIN E1609
ECOG-ACRIN Cancer Research Group
Grant: U10CA180820, U10180794, U10CA180821, U10CA180863,
ECOG-ACRIN Cancer Research Group
Grant: U10CA180888, UG1CA189859, UG1CA233163, UG1CA233180
ECOG-ACRIN Cancer Research Group
Grant: UG1CA233184, UG1CA233196, UG1CA233234, UG1CA233237
ECOG-ACRIN Cancer Research Group
Grant: UG1CA233270, UG1CA233331, UG1CA233373, UG1CA233320
ECOG-ACRIN Cancer Research Group
Grant: UG1CA233337
National Cancer Institute
Grant: P50CA12197310
Moffitt Cancer Center
Grant: Cancer Center Support Grant (CCSG) CA076292
Canadian Cancer Society Research Institute
Grant: 704970
NCI NIH HHS
Grant: U24 CA196172
NCI NIH HHS
Grant: UG1 CA233234
NCI NIH HHS
Grant: UG1 CA233320
NCI NIH HHS
Grant: U10 CA180863
NCI NIH HHS
Grant: UG1 CA233184
NCI NIH HHS
Grant: UG1 CA233270
NCI NIH HHS
Grant: UG1 CA233373
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: U10 CA180821
NCI NIH HHS
Grant: UG1 CA233331
NCI NIH HHS
Grant: R01 CA124515
NCI NIH HHS
Grant: R01 CA204419
NCI NIH HHS
Grant: UG1 CA233196
NCI NIH HHS
Grant: P30 CA076292
NCI NIH HHS
Grant: U10 CA180888
NCI NIH HHS
Grant: UG1 CA189859
NCI NIH HHS
Grant: UG1 CA233163
NCI NIH HHS
Grant: UG1 CA233180
National Institutes of Health
Grant: 3UG1CA233337-06S1
Yale Cancer Center NCTN LAPS
National Institutes of Health
Grant: 5U10CA180863-08
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network
National Institutes of Health
Grant: 1UG1CA233184-01
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
Croatian Science Foundation
Grant: 0000
Coordination reactions of macrocyclic ligands in solution
National Institutes of Health
Grant: 5UG1CA233196-03
Johns Hopkins University NCTN Lead Academic Site Program
National Institutes of Health
Grant: 3U10CA180888-03S1
SWOG Network Group Operations Center of the NCTN
National Institutes of Health
Grant: 3UG1CA233163-06S1
National Clinical Trials Network (NCTN) - Lead Academic Participating Site (LAPS)
National Institutes of Health
Grant: 5UG1CA233180-02
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
National Institutes of Health
Grant: 3U10CA180821-02S2
Alliance for Clinical Trials in Oncology Operations Center
National Institutes of Health
Grant: 3U10CA180820-02S3
ECOG-ACRIN Operations Center
National Institutes of Health
Grant: 5UG1CA233331-03
OSU as a Network Lead Academic Participating Site for the NCI NCTN
National Institutes of Health
Grant: 5UG1CA233234-06
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
National Institutes of Health
Grant: 5UG1CA233270-02
Vanderbilt Network Lead Academic Participating Site for the NCTN
National Institutes of Health
Grant: 1UG1CA233373-01
UNC Lead Academic Participating Site
National Institutes of Health
Grant: 5UG1CA189859-03
Minority-Based Community Oncology Research Program
National Institutes of Health
Grant: 5UG1CA233320-02
Northwestern University Lead Academic Participating Site
FWCI
1.49
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Additional file 1 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Additional file 2 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Additional file 2 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Additional file 3 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Additional file 3 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males